Advicenne S.A.
Paris Stock Exchange ALDVI.PA
Advicenne S.A. EBITDA for the year ending December 31, 2023: USD -6.89 M
Advicenne S.A. EBITDA is USD -6.89 M for the year ending December 31, 2023, a 34.75% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
-
Advicenne S.A. EBITDA for the year ending December 31, 2022 was USD -10.56 M, a 22.92% change year over year.
-
Advicenne S.A. EBITDA for the year ending December 31, 2021 was USD -13.70 M, a 19.74% change year over year.
-
Advicenne S.A. EBITDA for the year ending December 31, 2020 was USD -17.07 M, a -8.59% change year over year.
-
Advicenne S.A. EBITDA for the year ending December 31, 2019 was USD -15.72 M, a -176.54% change year over year.
Key data
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
Market news
Loading...
Paris Stock Exchange: ALDVI.PA
| CEO | Mr. Didier Laurens |
| IPO Date | Dec. 6, 2017 |
| Location | France |
| Headquarters | 3ème étage 262 |
| Employees | 21 |
| Sector | Health Care |
| Industries | |
Description
Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email